Background. Prostate specific antigen (PSA) does not appear to have the specificity to distinguish between benign prostate hyperplasia and cancer when the PSA is low. PSA density is thought by many to improve the specificity for cancer; however, this theory remains controversial. Methods. The autho
Experience with prostate-specific antigen in prostatic carcinoma
β Scribed by I. Romics; D. Bach
- Book ID
- 110567816
- Publisher
- Springer Netherlands
- Year
- 1991
- Tongue
- English
- Weight
- 370 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0301-1623
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: It is not yet known whether screening for the detection of early prostate carcinoma will reduce mortality rates. however, data are available to assess intermediate outcomes from screening, including the performance characteristics of the screening tests and shifts in disease stage.
## Abstract Prostateβspecific antigen (PSA), as measured in peripheral blood, is currently the most widely used marker for the assessment of tumor burden in the longitudinal study of patients with carcinoma of the prostate (PCA). Studies from other laboratories have led to the conclusion that a giv